Sarepta Therapeutics (NASDAQ: SRPT) shares rose 4.8% to $23.37 after the company announced the publication of Ebola and Marburg Phase I clinical study results in antimicrobial agents and chemotherapy. Share volume was 1.5 million, compared to an all-day average of 1.2 million.
